WuXi Biologics Clears FDA Inspection, Bolstering U.S. Commercial Supply Credentials
Event summary
- WuXi Biologics' Wuxi Mashan site passed a two-week FDA GMP inspection covering multiple approved biologics categories.
- The site has maintained a 100% success rate across 600+ regulatory audits over 13 years.
- WuXi operates 26 drug substance and 19 drug product facilities globally as of 2026.
- The company supports 1,064 integrated projects, including 78 in Phase III and 28 in commercial manufacturing.
The big picture
WuXi Biologics' latest FDA inspection success reinforces its position as a critical player in global biologics manufacturing. The company's ability to integrate drug substance and product manufacturing within single sites gives it an operational advantage as biopharma companies increasingly outsource complex commercial production. With over 20 biologics launched globally through its facilities, WuXi is becoming an indispensable partner for mid-to-large biotech firms seeking U.S. market access.
What we're watching
- Regulatory Momentum
- Whether WuXi can maintain its perfect audit record as global demand for commercial biologics supply grows.
- Capacity Expansion
- The pace at which WuXi will add new facilities to support increasing complex modality projects.
- Competitive Positioning
- How WuXi's integrated DS/DP capabilities will differentiate it from Western CRDMO competitors.
Related topics
